What's in Sight Sciences, Inc.'s pipeline?

Sight Sciences, Inc. has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Sight Sciences, Inc.'s portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sight-sciences-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Sight Sciences, Inc. — Portfolio Competitive Intelligence Brief

Sight Sciences, Inc. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Latanoprost plus adjunctive glaucoma medication	Latanoprost plus adjunctive glaucoma medication	marketed	Prostaglandin analog with adjunctive glaucoma agent	FP prostaglandin receptor (latanoprost component); adjunctive target unknown	Ophthalmology

Therapeutic area mix

Ophthalmology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Sight Sciences, Inc.:

Cite this brief

Drug Landscape (2026). Sight Sciences, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sight-sciences-inc. Accessed 2026-05-15.